Follow-up – Zahraa Khalifa
A new type 2 diabetes drug has been developed that works differently from other diabetes medications called terziparatide.
The drug controls blood sugar levels in two different ways, one by stimulating the release of a sugar-dependent insulin-releasing peptide and the other by stimulating the glucagon-like peptide receptor, both of which lower blood sugar levels and increase insulin sensitivity.
This drug is also effective in helping to lose weight by 20%, and is suitable for people with both diabetes and obesity. It is easy to use, as it is taken once a week in the form of an injection under the skin.
Compared to other glucagon-like peptide receptor agonists, it has a lower potential for side effects, most of which are associated with gastrointestinal disturbances, such as nausea, vomiting, and diarrhea.
However, there are some rare serious side effects, such as acute pancreatitis, so the drug should be stopped immediately after the occurrence of severe abdominal pain and a review of the attending physician.
It is important to note that this medication is not used for weight loss because it is designed for people with type 2 diabetes.
